Although this immunomodulatory activity exhibits an effective anticancer effect by cytotoxic CD8+ T cells for CRC treatment, antibody therapies have poor permeability in the tumor tissues, a long half-life, immune-related adverse effects, a large molecular weight, and a high cost, and require intravenous administration [15]. This evidence concerns the gene CD8A and neoplasm.